Education
About Us
Working with TipRanks
Follow Us
AN2 Therapeutics, Inc. (ANTX)
NASDAQ:ANTX
ANTX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.87 - $3.07
Previous CloseN/A
Volume42.38K
Average Volume (3M)67.19K
Market Cap
$37.62M
Enterprise Value-$42.38M
Total Cash (Recent Filing)$24.69M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.07
Next Earnings
May 07, 2025EPS Estimate
-0.26Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.72
Shares Outstanding30,098,720
10 Day Avg. Volume31,340
30 Day Avg. Volume67,186
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.90
P/FCF Ratio0.00
Enterprise Value/Market Cap-1.13
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda1.17
Forecast
1Y Price Target
$2.67Price Target Upside113.60% Upside
Rating ConsensusHold
Number of Analyst Covering5
---
AN2 Therapeutics, Inc. News
---
Bulls Say, Bears Say
Bulls Say
Drug EfficacyThe efficacy results for epetraborole in MAC NTM are convincing, with expectations of similar positive outcomes in Phase 3.
Financial StabilityAN2 reported results in line with consensus estimates, ending the year with ~$89M in cash and guiding to runway through 2027 under the current operating plans.
Market OpportunityAN2 Therapeutics anticipates unblinding Phase 3 results for their oral antibiotic candidate, which could lead to a significant market opportunity of over $1 billion.
Bears Say
Clinical Trial ChallengesThe key secondary endpoint of sputum culture conversion was not met; 6-month culture conversion was similar between arms.
Trial OutcomesThe culture conversion results for epetraborole were disappointing, although not unexpected.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ANTX FAQ
What was AN2 Therapeutics, Inc.’s price range in the past 12 months?
AN2 Therapeutics, Inc. lowest stock price was $0.87 and its highest was $3.07 in the past 12 months.
What is AN2 Therapeutics, Inc.’s market cap?
AN2 Therapeutics, Inc.’s market cap is $37.62M.
When is AN2 Therapeutics, Inc.’s upcoming earnings report date?
AN2 Therapeutics, Inc.’s upcoming earnings report date is May 07, 2025 which is in 10 days.
How were AN2 Therapeutics, Inc.’s earnings last quarter?
AN2 Therapeutics, Inc. released its earnings results on Mar 25, 2025. The company reported -$0.25 earnings per share for the quarter, beating the consensus estimate of -$0.27 by $0.02.
Is AN2 Therapeutics, Inc. overvalued?
According to Wall Street analysts AN2 Therapeutics, Inc.’s price is currently Undervalued.
Does AN2 Therapeutics, Inc. pay dividends?
AN2 Therapeutics, Inc. does not currently pay dividends.
What is AN2 Therapeutics, Inc.’s EPS estimate?
AN2 Therapeutics, Inc.’s EPS estimate is -0.26.
How many shares outstanding does AN2 Therapeutics, Inc. have?
AN2 Therapeutics, Inc. has 30,098,720 shares outstanding.
What happened to AN2 Therapeutics, Inc.’s price movement after its last earnings report?
AN2 Therapeutics, Inc. reported an EPS of -$0.25 in its last earnings report, beating expectations of -$0.27. Following the earnings report the stock price went up 1.333%.
Which hedge fund is a major shareholder of AN2 Therapeutics, Inc.?
Currently, no hedge funds are holding shares in ANTX
---
AN2 Therapeutics, Inc. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$2.67 (113.60% Upside)
$2.67 (113.60% Upside)
Hedge Fund Trend
Decreased
By 2.0M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $15.7K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▼ 3.6%
Last 30 Days ▼ 3.6%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-45.17%
12-Months-Change
Fundamentals
Return on Equity
-49.69%
Trailing 12-Months
Asset Growth
-33.63%
Trailing 12-Months
Company Description
AN2 Therapeutics, Inc.
AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menlo Park, California.
---
ANTX Stock 12 Month Forecast
Average Price Target
$2.67
▲(113.60% Upside)
Technical Analysis
Dyadic International
―
Outlook Therapeutics
―
Spero Therapeutics
―
X4 Pharmaceuticals
―
Iterum Therapeutics
―
Best Analysts Covering ANTX
1 Year
1 Year Success Rate
5/10 ratings generated profit
1 Year Average Return
-16.45%
reiterated a buy rating last month
Copying Roy Buchanan's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of -16.45% per trade.
---